Lundbeck-backed injectable bone graft developer Bonesupport has attracted $14m for a funding round led by an unnamed Scandinavian pension fund.

Galapagos has increased the target for its upcoming IPO on Nasdaq to $230m, while $55m of the stock could be bought by AbbVie and Johnson & Johnson.

BioCity Scotland announces plans to unite universities, the NHS, investors, pharmaceutical firms and others under one innovation hub.

Novo Seeds, Lundbeck, Merck and Astellas all exited EpiTherapeutics after it was acquired by biopharmaceutical firm Gilead.

Novo-backed CoLucid Pharmaceuticals secured $55m in the offering, and will use the proceeds to advance its migraine treatment through clinical trials.

The health services management company, founded by UPMC Health Plan and The Advisory Board Company, has targeted $100m for its initial public offering.

The cancer therapeutics developer, backed by Novo and Immunocore, raised the cash less than a year after closing a nine-figure series A round.